Patent ID: 8227421

Claim:
A peptide selected from the group having the formulae: [R 1 -A 0 , A 1 , A 2 , A 6 , A 8 , A 9 , A 10 , A 11 , A 12 , A 13 , A 15 , A 17 , A 19 , A 20 , A 21 , A 22 , A 23 , A 27 , A 28 , A 29 , A 30 ]hGH-RH(1-30)-R 2 wherein R 1 PhAc, PhF 5 Ac, CH 3 (CH 2 ) 10 CO, Ac, Tfa or Dca, A 0 is Dca, PhAc, PhF 5 Ac, (Dca-Ada), (CH 3 —(CH 2 ) 10 —CO-Ada), (Ac-Ada), (PhAc-Ada), or (PhF 5 Ac-Ada) ω-Ada, Amc, or is absent A 1 is L-Fpa, D-Fpa, Tyr, D-Tyr, His, D-His or Fpa5, A 2 is D-Arg, D-Har, D-Cit, or D-Amp, A 6 is Fpa, Fpa5, or Cpa, A 8 is Asn, D-Asn, Cit, D-Cit, Gln, D-Gln, Ser, D-Ser, Thr, D-Thr, Ala, D-Ala, N-Me-Ala, N-Me-D-Ala, Abu, D-Abu, or Aib, A 9 is Har, D-Har, Arg, D-Arg, Fpa, D-Fpa, His, D-His, Amp, D-Amp, Gup, or D-Gup, A 10 is di- or poly-fluorinated (on the aromatic ring) Phe, Fpa2, Fpa3, Fpa4, or Fpa5, A 11 is His, D-His, Arg, D-Arg, Cit, D-Cit, Har, D-Har, Amp, D-Amp, Gup, or D-Gup, A 12 is Lys, D-Lys, Lys(Me) 2 , Lys(iPr), Orn, D-Orn, Har, D-Har, Cit, D-Cit, Nle, D-Nle, Ala, or D-Ala, A 13 is Fpa, or Val, A 15 is Fpa, Gly, Ala, Abu, Aib, Nle, Gln, Cit, or His, A 17 is Leu or Glu, A 19 is Ala or Abu, A 20 is His, D-His, Arg, D-Arg, Har, D-Har, Amp, D-Amp, Cit, or D-Cit, A 21 is Lys, D-Lys, Lys(Me) 2 , Lys(iPr), Orn, D-Orn, Har, D-Har, Cit, or D-Cit, A 22 is Fpa, Leu, Tyr, Ala, or Aib, A 23 is Fpa, Leu, Tyr, Ala, or Aib, A 27 is Nle, Met, Leu, Ala, Abu, α-Apa, α-Ahea, or α-Aoc, A 28 is Arg, D-Arg, Har, D-Har, Ser, Asn, Asp, Ala, Abu, or Cit, A 29 is Arg, D-Arg, Har, or Agm, A 30 is, Arg, Ada, D-Arg, Har, Agm, or is absent, R 2 is —NH 2 , or —OH, provided that when A 17 is Leu and A 30 is Ada, then A 15 is other than Abu, also provided that if A 29 is Agm then A 30 and R 2 are absent, and if A 30 is Agm then R 2 is absent, and pharmaceutically acceptable salts thereof.